TO THE EDITOR I read with great interest the article by Krejsgaard et al. (2011) entitled ''Malignant Cutaneous T-Cell Lymphoma Cells Express IL-17 Utilizing the Jak3/Stat3 Signaling Pathway.'' The authors conclude that the expression of IL-17 by malignant T cells in cutaneous T-cell lymphoma (CTCL) lesions is promoted by the Jak3/Stat3 pathway. I find this conclusion to be misleading.
The authors studied the role of IL-17 in the pathophysiology of CTCL. Building on a previous study that showed IL-17 mRNA in 5 out of 10 biopsies from CTCL patients (Ciree et al., 2004) , the authors report that biopsies from 10 out of 13 of their CTCL patients expressed IL-17. To delineate the molecular basis of IL-17 expression in CTCL, the authors explored the role of cytokines that signal through receptors with the g chain (g c ) subunit (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21) because these cytokines have been implicated in the pathogenesis of CTCL. For example, g c -cytokines promote the ex vivo survival and proliferation of malignant T cells (Krejsgaard et al., 2011) . A unique feature of g c -cytokines is that these are the only cytokines to use Jak3 signaling (Rochman et al., 2009 ). Importantly, malignant T cells from a subset of CTCL patients were found to contain mutations in Jak3 that made them constitutively active (Cornejo et al., 2009) ; this finding implicates g c -cytokines because other than a constitutively active Jak3, the only other way to activate the Jak3 signaling pathway is through g c -cytokine binding. To assess the role of g c -cytokines in IL-17 expression, the authors used two malignant T-cell lines (SeAx and SeZ4) derived from CTCL patients. The authors report that both IL-2 and IL-15 increased IL-17 expression. Further, IL-2/IL-15-mediated expression of IL-17 was blocked by inhibiting Jak3 both pharmacologically using Jak3 inhibitors as well as genetically by Jak3-directed siRNA. Although these data show the involvement of Jak3 in IL-2-and IL-15-mediated expression of IL-17, they do not establish a pivotal role of Jak3 activation in IL-17 expression because other Jak3 activating g c -cytokines did not affect the IL-17 expression (as shown in Figure S2 provided by the authors).
Having said this, I would like to point out that the authors did not adequately examine the role of other g c -cytokines in IL-17 expression. Although the authors show that these cytokines do not increase IL-17 expression ( Figure S2 ), they do not provide data on Jak3 activation. As each cytokine was tested only at a single concentration, it is possible that Jak3 was not activated at the concentration for each cytokine used in the experiment shown in Figure S2 . The authors should have prepared a dose response curve for each individual cytokine to ensure that the concentration that they used were effective in activating Jak3. This is important because although the concentrations of various cytokines selected by the authors may be sufficient to activate their cognate receptors in normal cells, these concentrations may not be sufficient to activate their corresponding receptors once a T cell has undergone malignant transformation. Thus, in the absence of data showing the activation of Jak3 by these cytokines, it cannot be concluded that other Jak3activating cytokines do not modulate IL-17 expression.
I also want to point out that CP-690,500, which was used in this study and is widely accepted in the literature as a Jak3 selective inhibitor, is no longer considered to be selective for Jak3. Recent data, in both enzyme-based and cell-based assays, indicate that CP-690,550 inhibits Jak1, Jak2, and Jak3 with similar affinities (IC 50 ¼ 3.2 nM for JAK1, IC 50 ¼ 4.2 nM for JAK2, and IC 50 ¼ 1.6 nM for JAK3; Meyer et al., 2010) . Similarly, WHI-P154, the other Jak3 inhibitor used in this study, inhibits Jak2 at comparable concentrations (at 30 mM, WHI-P154 showed a 23 þ 4% inhibition of Jak3 and 16 ± 3.2% of Jak2; Carbonnelle et al., 2009 ).
An important question raised by this study pertains to the variation of expression of IL-17 in CTCL patients. It is clear that IL-17 is not expressed in all CTCL patients. The question arises whether IL-17 expression denotes a subtype of CTCL and whether levels of IL-17 correlate with disease severity. This information would be useful in designing pharmacological treatments based on molecular phenotypes of the tumor.
In summary, the main conclusion that can be drawn from the data presented by Krejsgaard et al. (2011) is that IL-2/IL-15 mediate IL-17 expression through Jak3 signaling. Whether Jak3 activation alone is sufficient to promote IL-17 expression remains to be determined. Cornejo MG, Kharas MG, Werneck MB et al. (2009) Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. 
TO THE EDITOR
We are pleased at the interest that Kwatra (2011) has shown in our article ''Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway'' (Krejsgaard et al., 2011) and welcome the opportunity to discuss the conclusions drawn from the study. Kwatra (2011) argues that because only the two IL-2 receptor b chain (IL-2Rb) cytokines, IL-2 and IL-15, but not the other Jak3-activating cytokines utilizing the common cytokine receptor g chain (g c ) increase the expression of IL-17, it is misleading to conclude that the Jak3/signal transducer and activator of transcription 3 (Stat3) pathway promotes the malignant expression of IL-17 in cutaneous T-cell lymphoma (CTCL). Instead, he suggests that the conclusion that can be drawn from the study is that IL-2 and IL-15 mediate IL-17 expression through Jak3 signaling. Of notice, this is in agreement with our statement in this article, namely that ''Our results show that the IL-2Rb cytokine-induced expression of IL-17 is mediated through a Jak3/Stat3dependent mechanism''. Thus, the question is, can Jak3 also promote the expression of IL-17 in the absence of IL-2Rb cytokines?
First of all, the malignant T cells spontaneously produced low amounts of IL-17 after cytokine starvation, indicating that IL-17 is not exclusively regulated by IL-2 and IL-15. Second, although the activity of Jak3 is greatly increased after stimulation with IL-2Rb cytokines, it exhibits constitutive activ-ity in the malignant CTCL cells even after cytokine starvation (Krejsgaard et al., 2006) . This is possibly through a cytokine-independent mechanism involving loss of regulatory control by the protein tyrosine phosphatases and/or suppressors of cytokine signaling (Zhang et al., 2000; Brender et al., 2005) . Third, Jak3 knockdown by small interfering RNA inhibited the spontaneous IL-17 production. Therefore, we do not think that it is misleading to conclude that our results indicate Jak3 promotes the expression of IL-17 by the malignant T cells.
As Kwatra (2011) points out, we are aware that WHI-P154 inhibits Jak2 and Jak3 at comparable concentrations and that recent data have indicated that CP-690,550 inhibits Jak1 and Jak2 with similar affinities as Jak3 (Carbonnelle et al., 2009; Meyer et al., 2010) . However, because we substantiated the results obtained using the Jak3 inhibitors by the Jak3-directed small interfering RNA, we think that it justifiable to conclude that Jak3 is involved in promoting the expression of IL-17. That said, these data do not exclude that the expression of IL-17 can also be modulated with other members of the Jak family.
In the study, we primarily focused on the role of IL-2Rb cytokines in the malignant secretion of IL-17 and concur that further studies are needed to fully establish if other members of the g c family can modulate the expression of IL-17 by the malignant T cells. Nevertheless, our data show that relatively high concentrations of IL-4, IL-7, IL-9, and IL-21 do not significantly increase their secretion of IL-17 in vitro. Of notice, we have confirmed that IL-21 activates the Jak3/Stat3 pathway in the malignant T cells with minimal influence on the expression of IL-17 (data not shown). In addition, we found that some patients were IL-17 negative even though the malignant T cells exhibited constitutive activation of Stat3. Accordingly, as discussed in the article, the capacity of the Jak3/Stat3 pathway to promote IL-17 expression seems to be regulated by additional factors. It is possible that some cytokines, like IL-21, not only activate the Jak3/Stat3 pathway but also activate other pathways that modulate the Jak3-dependent IL-17 expression. Moreover, it seems likely that the expression of IL-17 is also modulated by other signaling pathways and transcription factors that are often known to be aberrantly regulated in CTCL (Sors et al., 2006; Krejsgaard et al., 2009; Kopp et al., 2010) . In our opinion, the present data suggest that Jak3 promotes the expression of IL-17 by the malignant CTCL cells both in the presence and in the absence of IL-2 and IL-15. Therefore, we conclude in the article that Jak3 promotes the expression of IL-17, but we also clearly highlight that this is regulated by other factors.
